Orbital implant receives innovation award

Article

The new AlphaSphere Orbital Implant ophthalmic device has been awarded the 2010 Alpha Award for Innovation In Engineering & Technology presented by the Engineering Society of Detroit.

The new AlphaSphere Orbital Implant ophthalmic device has been awarded the 2010 Alpha Award for Innovation In Engineering & Technology presented by the Engineering Society of Detroit.

Art Brodie, Executive Vice President, Business Development at Addition Technology, the maker of the product said: “We view the engineering, materials and design of the AlphaSphere device to be a quantum leap forward in orbital implant technology. Although AlphaSphere was only launched in the second half of 2009, we have already seen surgeons at Bascom Palmer, Yale and Mass. Eye & Ear to name a few begin to use the device, and though the results are short-term, the light-weight, smooth and bio-integratable characteristics have generated very favourable feedback.”

The implant is a new entry into an historical market that dates back to 1884. It is the first orbital implant device made from a novel poly-HEMA bio-material (PHEMA) that biointegrates into the eye socket capsule yet resists bio-integration in its posterior hemisphere to provide S motility to a prosthetic eye. Since the majority of its composition is water, AlphaSphere’s ability to provide compliance in matching natural organ tissue is claimed by its makers to be unique in comparison to other orbital implant products due to its soft, smooth and pliable exterior. A major feature is the ability to directly suture into the endo-skeletal, anterior surface.

www.AdditionTechnology.com will give you more information.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.